NewLeaf Symbio…
ProfileJobs

NewLeaf Symbiotics

Suggest Edit
    • Manufacturing & Industrialagriculturebiotechresearch
    NewLeaf Symbiotics was formed to develop and commercialize one of the most prevalent, beneficial bacteria found in nature: PPFMs (Pink Pigmented Facultative Methylotrophs). NewLeaf Symbiotics is the exclusive licensee of a number of patents on the use of this family of bacteria. NewLeaf Symbiotics has also filed its own related patents, and is actively developing new technologies related to PPFMs. The Company is engaged in laboratory, greenhouse, and field product trials.
    Total Funding
    $57.6 M
    Type
    Private
    HQ
    St. Louis, US
    Founded
    1999
    Size (employees)
    29 (est)-3%
    Website
    newleafsym.com
    NewLeaf Symbiotics was founded in 1999 and is headquartered in St. Louis, US
    Report incorrect company information

    Key People/Management at NewLeaf Symbiotics

    Thomas Laurita

    Thomas Laurita

    President and CEO
    Stephen Kahn

    Stephen Kahn

    Senior VP and CFO
    Gregg Bogosian

    Gregg Bogosian

    Chief Scientist
    Marcus Jones

    Marcus Jones

    Vice President, Product Development
    Jim Budzynski

    Jim Budzynski

    VP Business Development and CTO

    NewLeaf Symbiotics Office Locations

    NewLeaf Symbiotics has an office in St. Louis
    St. Louis, US (HQ)
    1005 North Warson Road
    Show all (1)
    Report incorrect company information

    NewLeaf Symbiotics Financials and Metrics

    Summary Metrics

    Founding Date

    		1999

    Total Funding

    		$57.6 m

    Latest funding size

    		$6 m

    Time since last funding

    		9 months ago

    Investors

    		RockPort Capital, Otter Capital, Monsanto Growth Ventures (MGV), Open Prairie, The Yard Ventures, Palo Alto Investors, Pangaea Ventures, Lewis & Clark Ventures
    NewLeaf Symbiotics's latest funding round in September 2017 was reported to be $6 m. In total, NewLeaf Symbiotics has raised $57.6 m
    Show all financial metrics
    Report incorrect company information

    Competitors

    ProtoKinetix
    Health - Public
    MPI Research
    Health - Subsidiary
    Bioceres
    Technology - Public
    Entia Biosciences
    Health - Public
    Compare competitors

    NewLeaf Symbiotics News and Updates

    July 10, 2017

    NewLeaf Symbiotics nabs $24 mln Series C

    St. Louis, Missouri-based NewLeaf Symbiotics, an agricultural biotech company, has secured $24 million in Series C financing. Monsanto Growth Ventures and Otter Capital led the round with participation from other backers that included Lewis & Clark Ventures, Rockport Capital, Pangaea Ventures an…
    Report incorrect company information
    Download PDF